Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial
International Journal of Radiation Oncology*Biology*Physics · 2026-09 · 126 (1) · S126-S127
DOI: 10.1016/j.ijrobp.2026.06.186 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2026-09. Verfasst von Z. Zhang und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Zhang, Z., Zheng, X., Cao, X., Simayi, S., & Ge, H. (2026). Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial. International Journal of Radiation Oncology*Biology*Physics, 126(1), S126-S127. https://doi.org/10.1016/j.ijrobp.2026.06.186
Vancouver
Zhang Z, Zheng X, Cao X, Simayi S, Ge H. Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial. International Journal of Radiation Oncology*Biology*Physics. 2026;126(1):S126-S127. doi:10.1016/j.ijrobp.2026.06.186
BibTeX
@article{Zhang2026,
author = {Zhang, Z. and Zheng, X. and Cao, X. and Simayi, S. and Ge, H.},
title = {Osimertinib Combined with Stereotactic Body Radiotherapy vs. Osimertinib Alone in Advanced EGFR-Mutant Non-Small Cell Lung Cancer: A Phase II Randomized Controlled Trial},
journal = {International Journal of Radiation Oncology*Biology*Physics},
year = {2026},
volume = {126},
number = {1},
pages = {S126--S127},
doi = {10.1016/j.ijrobp.2026.06.186}
}
EUVIMED